// Biotech and Pharma Therapeutics
/cloudfront-us-east-2.images.arcpublishing.com/reuters/G2WXGSOW2NIANG4CK7HK6T3RLI.jpg)
ChemoCentryx’s drug gets U.S. FDA nod for treating rare autoimmune disease
ChemoCentryx Inc said on Friday the U.S. health agency approved its lead drug for treating a rare, fatal autoimmune disease, sending the biopharmaceutical company’s shares up by more than 70%.
www.reuters.com
Supporting Patient Adherence Through Electronic Prior Authorization and First Fill Copay Programs
Today’s guest post comes from David Fidler, Senior Director of Product Innovation at ConnectiveRx. David discusses how electronic prior authorization (ePA) and first-fill, buy-down programs can boost patient adherence to specialty therapies.
www.drugchannels.net
Biohaven’s Nurtec, with dual migraine approvals, hits $136M in quarterly sales and leads the pack in market share
Biohaven’s migraine drug Nurtec ODT has been on a roll since becoming the first medicine to win a dual FDA approval to both treat and prevent migraines. Now, the company is posting sales figures that might make some of its Big Pharma rivals in the migraine field jealous.
www.fiercepharma.com
/https%3A%2F%2Fspecials-images.forbesimg.com%2Fimageserve%2F615e1eb6ce39f3eabb878539%2F0x0.jpg)
1 In 10 Americans Turn To Social Media For Health Information, New Survey Shows
Though almost no one says they trust social media for health information, approximately 1 in 10 Americans surveyed say they get their health information via social media.
www.forbes.com
Voyager Therapeutics’ strategy shift to gene therapy tech leads to a Pfizer alliance - MedCity News
The gene therapy pipeline of Voyager Therapeutics has hit several setbacks in the past year, but a strategy shift to its capsid technology is now showing promise. Pfizer has signed on as partner in a wager that Voyager’s tech holds the key to delivery of gene therapies for cardiovascular and neurolo…
medcitynews.com
// 4th Industrial Revolution
Contributed: Technology is helping physicians and pharma to better coexist
Healthcare is undoubtedly one of the most complex and nuanced industries there is, especially in the U.S. So, it is no surprise that the relationship between physicians and pharma is complicated at best.
www.mobihealthnews.com
Teladoc’s latest primary care offering, Primary360, available to payers
Teladoc is pitching the expanded service as a way to improve primary care access. Virtual care giant Teladoc Health announced Wednesday that its primary care offering, Primary360, is now available for health plans, employers and other payers.
www.mobihealthnews.com
A Visual Guide to Investing in Psychedelics
This graphic provides a visual guide to investing in psychedelics, breaking down each sector and the companies that operate within them.
www.visualcapitalist.com
Why Healthcare IT Must Embrace Full-Stack Observability for an Increasingly Digital Future
To forge a new path forward, health IT needs to implement strategies focused on full-stack observability with the business context in order to ensure the vital applications that keep healthcare running are safe, always available, seamless and secure.
hitconsultant.net
// Business & Markets
Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
Xeris Pharmaceuticals, Inc. (“Xeris”), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”).
www.businesswire.com
Poolbeg Pharma launches AI programme with Eurofins Genomics
London-based infectious disease pharmaceutical company, Poolbeg Pharma, has announced their deal with testing and support specialist, Eurofins Genomics, according to Proactive Investors.
www.pharmatimes.com
Xenon Pharma secures $300M capital raise via equity offering
Xenon Pharmaceuticals (XENE) has priced its public offering of 8,474,577 common shares and, pre-funded warrants to purchase up to 1,694,915 common shares.The common shares and...
seekingalpha.com
Gene therapy developer gets chance at a comeback with Pfizer deal
Voyager Therapeutics recently scrapped much of its pipeline and replaced top executives. Now, a Pfizer deal on new technology gives investors hope.
www.biopharmadive.com
Three New Nasdaq Tickers and MPM Capital Secures $850 Million to Impact Oncology | BioSpace
After weeks of slowing initial public offerings within the biopharma and life sciences industries, within the last 24 hours, three companies announced plans to list their stocks on the Nasdaq. Cognition Therapeutics, Pyxis Oncology and IsoPlexis Corp. all announced IPO plans.
www.biospace.com
// Legal & Regulatory
.jpeg)
FDA offers best practices for patient-facing alerts on medical device vulnerabilities
The agency noted that communications about cyber risks should be easy to understand and readily available online.
www.healthcareitnews.com
FDA halts all Allogene cell therapy trials after chromosome problem detected - MedCity News
All of Allogene Therapeutics’ clinical trials are now under an FDA clinical hold. The halt was handed down after one patient in the company’s most advanced study developed what the company described as a “chromosomal abnormality.”
medcitynews.com
FDA Reaches a Milestone in Generic Drug Approvals
In less than 4 years, the FDA has approved more than 100 generic drug applications through a pathway designed to encourage and expedite the development and marketing of generic drugs that have little or no competition.
jamanetwork.com
Health Privacy and Our Ambivalent Tech-Embrace - Lessons for Digital Health Innovators - HealthPopuli.com
A new look into Americans’ views on health privacy from Morning Consult provides a current snapshot on citizens’ concerned embrace of technology — worried pragmatism, let’s call it. This ambivalence will flavor how health citizens will adopt and adapt to the growing digitization of health care, and…
www.healthpopuli.com
// Research & Development
Researchers demonstrate vaccination approach in mice that could prevent future coronavirus outbreaks
Researchers in Japan have developed a vaccination strategy in mice that promotes the production of antibodies that can neutralize not only SARS-CoV-2 but a broad range of other coronaviruses as well. If successfully translated to humans, the approach, to be published October 8, in the Journal of Exp…
medicalxpress.com
Nanotechnology offers alternative ways to fight COVID-19 pandemic with antivirals - Nature Biotechnology
A new wave of funding focuses on antiviral nanomaterials as pandemic countermeasures.
www.nature.com
Yale spinout shows how targeting cancer cells’ acidic environment might enhance immunotherapy
Yale University spinout Cybrexa Therapeutics has developed a peptide-drug conjugate that, instead of aiming for a specific antigen, targets the acidic environment of cancer cells to deliver a toxic payload. The drug improved the efficacy of checkpoint inhibitors in mouse models of cancer.
www.fiercebiotech.com
Algorithmic app could head off suicides of high-risk adolescents
Researchers have demonstrated the feasibility of AI-based smartphone interventions for young people who have attempted suicide and may try again. While the subjects were simulated patients, the preclinical work also succeeded in showing that Bayesian network modeling is “an accurate and very efficient branch of AI in psychiatry and clinical psychology,” the authors state.
aiin.healthcare
Mirati teams with Sanofi on PhI/II trial for KRAS treatment combo; AbbVie loses in latest Humira biosimilar development
Mirati and Sanofi on Friday announced their new non-exclusive, clinical collaboration to evaluate combining Mirati’s investigational KRAS G12C inhibitor adagrasib with Sanofi’s investigational SHP2 inhibitor RMC-4630 in an upcoming Phase I/II study. Sanofi is taking responsibility for sponsoring and…
endpts.com
// Politics
Why Sweden Is Suspending The Moderna Shot For Those Under 30
Sweden announced on Tuesday that it would temporarily suspending the use of Moderna’s COVID-19 vaccine for people under 30. It is unclear how the Nordic recommendations will affect other EU states’ recommendations after Moderna was declared safe to use as a booster shot for those 18 and older six
www.ibtimes.com
Study shows Medicaid expansion increased access to bariatric surgery for obesity
Following the Affordable Care Act (ACA) Medicaid expansion, access to bariatric surgery as a treatment for obesity increased by 31% annually for lower-income Medicaid-covered and uninsured white adults age 26 to 64 but not for Hispanic and Black adults, according to research conducted by scientists…
medicalxpress.com
